Federal Office of
Consumer Protection
and Food Safety

European Union
Reference Laboratory
supported by the

European Commission

Dr. Ulrike Mülow-Stollin
Proficiency Testing Coordinator

Federal Office of Consumer Protection and Food Safety
Berlin Office • P.O. Box 11 02 60 • 10832 Berlin • Germany

COMPOSED BY Dr. U. Mülow-Stollin
PHONE +49 (0)30 18445-8715
FAX +49 (0)30 18445-8099
E-MAIL ulrike.muelow-stollin@bvl.bund.de

YOUR REFERENCE
YOUR MESSAGE FROM

OUR REFERENCE 502.50401.0.344096
(please indicate in reply)

DATE 1st April 2021

Proficiency Test on "Precision and accuracy in the analysis of standard solutions" - STRD0521

Dear colleagues,

In our function as National and European Union Reference Laboratory, we are organising a proficiency test on the determination of select veterinary drugs of group B according to Annex I of Directive 96/23/EC in standard solutions. This proficiency test (PT) will enable the participants to check the standard solutions they apply in routine analyses. The short name of this PT will be: STRD0521. The study is scheduled to start in May 2021 and will be directed to all National Reference Laboratories (NRLs) in the Member States of the European Union, to the official laboratories in Germany, as well as to official laboratories in certain Third Countries with responsibilities for the substance groups B2a, B2b, and B2e. Please be aware that the projected starting date might be subject to change due to restrictions caused by the COVID-19 pandemic. Of course, all participants will be informed of any postponement. The deadline for the submission of the test results will be four weeks from the shipment. The exact date will be communicated in the protocol to be send together with the samples.

The test items will contain an unknown number and amount of analytes. Every standard solution will only contain analytes of a single substance group. The substance groups of interest for this PT are anthelmintics (B2a), coccidiostats (B2b) and NSAIDs (B2e). All analytes classified as minimum required and recommended, which are contained in the

samples will be taken into consideration for the proficiency assessment (Table 1). It is also possible to participate only for a selection of the three substance groups, if your laboratory is not responsible for all of them. You will be asked to indicate which substance groups you would like to participate for during the registration process.

Table 1: Classification of anthelmintics, coccidiostats and NSAIDs as minimum required and recommended. If not explicitly given, the relevant residues are the marker residues laid down in Commission Regulation (EU) No 37/2010.

substance group	*minimum required*	*recommended*
B2a - anthelmintics	abamectin closantel doramectin fenbendazole ivermectin levamisole albendazole moxidectin nitroxinil rafoxanide thiabendazole triclabendazole	clorsulon emamectin eprinomectin flubedazole mebendazole oxibendazole oxyclozanide
B2b - coccidiostats	diclazuril lasalocid maduramicin monensin narasin nicarbazin as 4,4'-dinitrocarbanilide robenidine salinomycin	amprolium clopidol decoquinate halofuginone ipronidazole nequinate semduramycin toltrazuril
B2e - NSAIDs	phenylbutazone flunixin, flunixin-hydroxide diclofenac 4-methylamino antipyrine tolfenamic acid carprofen ibuprofen naproxen meloxicam	oxyphenbutazone ketoprofen vedaprofen mefenamic acid niflumic acid flufenamic acid 4-formylamino antipyrine

All participants will be provided with a set of samples consisting of a total of six standard mixes. One half of the solutions of the sample set will be labelled as the PT test items. The remaining half will be made up of identically prepared mix solutions labelled as test mixes. The rationale is that the participants conduct their preliminary experiments, e.g. to identify a suitable calibration interval on the test mixes before performing the decisive measurements on the samples labelled as PT test items. Results shall be submitted only for the latter. More details will be provided in the proficiency testing protocol accompanying the samples.

A short report comprising an overview of the participants' results and a preliminary information on the participants' performance will be sent within four weeks after the deadline for result submission. The participants will then be requested to check their submitted results before the final report will be prepared and made available in November 2021. In the report

on results the participants will only be referred to by their lab codes. All statistical data evaluation connected to proficiency testing parameters will be carried out using robust methods. The proficiency testing organiser reserves the right to provide additional evaluations for information purposes. For performance evaluation the EURL point-score system, which differentiates between banned/non-authorised substances and MRL-substances, will be used. Further information can be gathered from the common protocol for proficiency testing available on the FIS-VL and the common EURL website.

To register for participation in proficiency test STRD0521, please fill in the registration form available at https://ec.europa.eu/eusurvey/runner/STRD0521Registration no later than 30 April 2020. You will receive a confirmation of registration after that date. Please also fill out the registration form, if you do not intend to participate in the proficiency test or if you are not the correct contact person. The password for the registration form is given in the e-mail announcing the PT.

With registration for STRD0521 participants consent to the publication of their results in an anonymous form by the organiser of the proficiency test. In addition, the results of the NRLs participating in this proficiency test may be provided in a non-anonymous form to the European Commission (DG SANTE) for internal use, as well as to the competent authorities of the Member States (according to Article 94, 2.(c), Regulation (EU) 2017/625). Analogously, the results of the German official laboratories may be provided in a non-anonymous form to the German competent authorities for internal use (according to Article 101, 1.(c), Regulation (EU) 2017/625).

In case you are not the correct contact person for this invitation, please forward this letter to the person/institute in charge or to other official labs that could be interested in participating. Thank you!

Yours sincerely,
On behalf of BVL

Dr. Ulrike Mülow-Stollin

Annex